Explore how the landscape of prostate cancer management is being reshaped by private equity’s foray into urology practices, and what it means for patients facing new diagnoses.
– by James
Note that James is a diligent GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
The immediate effects of private equity acquisition of urology practices on the management of newly diagnosed prostate cancer.
Faraj et al., Cancer Med 2023
DOI: 10.1002/cam4.6788
Study Summary:
A study investigated the impact of private equity acquisition of physician practices on healthcare spending and service utilization in men with prostate cancer. The research involved a retrospective cohort study using a 20% sample of national Medicare claims, focusing on patients diagnosed from 2014 to 2019. The primary outcome measured was prostate cancer spending within the first year post-diagnosis, while secondary outcomes included treatment usage and diagnostic testing (e.g., imaging, genomics).
Results:
- Sample included 409 men from acquired practices and 4021 men from nonacquired practices.
- No significant difference in spending was found post-acquisition ($1182 difference, p=0.36).
- Treatment usage did not change significantly (3.7% difference, p=0.30).
- Diagnostic testing usage did not significantly change for treated (-5.5% difference, p=0.12) or conservatively managed patients (-2.0% difference, p=0.82).
Importance:
The study suggests that private equity acquisition of urology practices does not lead to increased prostate cancer spending or overutilization of treatments and diagnostics in the first year. This counters concerns that such acquisitions might drive up healthcare costs due to increased service use.
Contribution to Literature:
This research contributes to the understanding of how private equity acquisitions affect healthcare delivery and costs, providing evidence that, at least in the short term, there is no significant impact on spending or service use in prostate cancer management.